MX2023010897A - Antagonista del receptor de melanocortina subtipo 2 (mc2r) para el tratamiento de enfermedades. - Google Patents

Antagonista del receptor de melanocortina subtipo 2 (mc2r) para el tratamiento de enfermedades.

Info

Publication number
MX2023010897A
MX2023010897A MX2023010897A MX2023010897A MX2023010897A MX 2023010897 A MX2023010897 A MX 2023010897A MX 2023010897 A MX2023010897 A MX 2023010897A MX 2023010897 A MX2023010897 A MX 2023010897A MX 2023010897 A MX2023010897 A MX 2023010897A
Authority
MX
Mexico
Prior art keywords
disease
treatment
mc2r
antagonist
receptor
Prior art date
Application number
MX2023010897A
Other languages
English (en)
Spanish (es)
Inventor
Christine Ferrara-Cook
Alan S Krasner
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of MX2023010897A publication Critical patent/MX2023010897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023010897A 2021-03-19 2022-03-16 Antagonista del receptor de melanocortina subtipo 2 (mc2r) para el tratamiento de enfermedades. MX2023010897A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163310P 2021-03-19 2021-03-19
US202263298571P 2022-01-11 2022-01-11
PCT/US2022/020543 WO2022197798A1 (en) 2021-03-19 2022-03-16 Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

Publications (1)

Publication Number Publication Date
MX2023010897A true MX2023010897A (es) 2023-09-27

Family

ID=83321094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010897A MX2023010897A (es) 2021-03-19 2022-03-16 Antagonista del receptor de melanocortina subtipo 2 (mc2r) para el tratamiento de enfermedades.

Country Status (11)

Country Link
US (2) US12280046B2 (enExample)
EP (1) EP4308553A4 (enExample)
JP (2) JP2024510260A (enExample)
KR (1) KR20230159443A (enExample)
AU (1) AU2022240609A1 (enExample)
BR (1) BR112023018816A2 (enExample)
CA (1) CA3211644A1 (enExample)
IL (1) IL305952A (enExample)
MX (1) MX2023010897A (enExample)
TW (1) TWI916531B (enExample)
WO (1) WO2022197798A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
EP4634176A1 (en) * 2022-12-16 2025-10-22 Crinetics Pharmaceuticals, Inc. Crystalline melanocortin subtype-2 receptor (mc2r) antagonist
PE20260134A1 (es) * 2023-05-19 2026-01-21 Crinetics Pharmaceuticals Inc Composiciones y metodos para el tratamiento de la hiperplasia suprarrenal congenita

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6890940B2 (en) 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US20030158209A1 (en) 2001-10-09 2003-08-21 Neurocrine Biosciences Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US6664273B2 (en) 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2003068738A1 (en) 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
JP2005534632A (ja) 2002-05-10 2005-11-17 ニューロクライン バイオサイエンセズ， インコーポレイテッド メラノコルチンレセプターリガンドとしての置換ピペラジン
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
NZ544820A (en) 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
EP1663232B1 (en) 2003-09-09 2007-10-03 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
CA2625877A1 (en) 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PT2344474E (pt) 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2715754B1 (en) 2011-05-31 2015-07-29 Linak A/S Actuator
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
EP3480198B1 (en) 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
US11377436B2 (en) 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
SG11202003407VA (en) 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
WO2021091788A1 (en) 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
JP7672406B2 (ja) 2019-12-18 2025-05-07 クリネティックス ファーマシューティカルズ，インク． Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
WO2023163945A1 (en) 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
EP4634176A1 (en) 2022-12-16 2025-10-22 Crinetics Pharmaceuticals, Inc. Crystalline melanocortin subtype-2 receptor (mc2r) antagonist

Also Published As

Publication number Publication date
US20250367190A1 (en) 2025-12-04
TWI916531B (zh) 2026-03-01
US12280046B2 (en) 2025-04-22
CA3211644A1 (en) 2022-09-22
IL305952A (en) 2023-11-01
EP4308553A4 (en) 2025-01-22
AU2022240609A1 (en) 2023-09-28
JP2024510260A (ja) 2024-03-06
KR20230159443A (ko) 2023-11-21
US20220313691A1 (en) 2022-10-06
WO2022197798A1 (en) 2022-09-22
EP4308553A1 (en) 2024-01-24
TW202302108A (zh) 2023-01-16
BR112023018816A2 (pt) 2023-10-31
JP2026009936A (ja) 2026-01-21

Similar Documents

Publication Publication Date Title
BR112023018816A2 (pt) Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
MX2023008954A (es) Inhibidores de los receptores erbb.
ZA202204284B (en) Inhibitors of raf kinases
SMT202500435T1 (it) Antagonista del recettore crf1, formulazioni farmaceutiche e forme solide dello stesso per il trattamento dell'iperplasia surrenalica congenita
EP4556067A3 (en) Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL183160A0 (en) Indazole-carboxamide compounds
JOP20220329A1 (ar) مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي
EP4603142A3 (en) Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
IL180979A0 (en) Isoindoline compounds and methods of making and using the same
JO3346B1 (ar) مواد مضادة C5aR
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
NO20053111L (no) Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
MX2024007444A (es) Inhibidores de cinasa met.
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
EP4480485A3 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
CR20240353A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
TW200738232A (en) Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
MX2025011804A (es) Antagonista del receptor de subtipo 2 de melanocortina (mc2r) para el tratamiento del sindrome de cushing dependiente de acth
WO2020106751A8 (en) Inhibitors of gli1 as therapeutic agents
CA3286979A1 (en) Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of acth-dependent cushing's syndrome
PH12021550323A1 (en) Dendrimer formulations